Cabaletta Bio, Inc. (CABA) is a clinical-stage biotechnology company that specializes in the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company operates on the forefront of medical research, leveraging state-of-the-art technology to address unmet medical needs and improve patient outcomes.
Founded in 2017 with headquarters in Philadelphia, Pennsylvania, Cabaletta Bio, Inc. is committed to the discovery and advancement of novel cellular immunotherapies specifically designed to treat autoimmune diseases. These diseases come about as a result of the immune system attacking the body's own cells, and they can lead to serious chronic conditions or life-threatening complications. Some of the autoimmune diseases that Cabaletta is working on include Pemphigus Vulgaris, Mucosal Pemphigoid, and hemophilia A, among others.
A distinctive element of Cabaletta’s approach is their focus on creating CAAR T (Chimeric AutoAntibody Receptor T cell) therapies. CAAR T therapy uses a patient’s own immune cells, that have been engineered to express a receptor, to recognize and destroy only the cells that are causing the autoimmune disease, leaving the healthy cells untouched. This approach is aimed at providing a targeted, potent, and durable resolutive response to a spectrum of autoimmune diseases. It is inspired by the proven success of CAR T cell therapy technology, an innovation in cancer treatment that has shown outstanding results in certain types of blood cancers.
The company received Orphan Drug Designation from the US Food and Drug Administration for its lead product, DSG3-CAART, for treatment of Pemphigus Vulgaris, in 2020. It plans to expand the application of its CAAR T platform into additional B cell-mediated autoimmune indications.
Cabaletta Bio, Inc. is a mission-driven company, and a pioneering leader in the field of autoimmune disease treatment research. With a commitment to scientific rigour and a dedication to translating discoveries into therapies, Cabaletta is working hard to revolutionize the treatment of autoimmune diseases and bring change to the lives of those affected. Its continuous innovations, strong scientific collaborations, and robust intellectual property portfolio point to a promising future for the company and those it serves. In conclusion, Cabaletta Bio, Inc. is not just a biotechnology company, but a beacon of hope for patients around the globe suffering from autoimmune diseases.